US EditionTelesis Bio Inks Regeneron Deal - San Diego Business Journal
Summary by San Diego Business Journal
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
SAN DIEGO – Nucleic acid synthesis technology company Telesis Bio, Inc., (OTC Pink: TBIO) recently took another step in its business transformation, inking a licensing agreement with Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN). The agreement, financial terms undisclosed, will see Regeneron use Telesis’ nucleic acid synthesis platform Gibson SOLA in its core research and development facilities, […]
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
